var data={"title":"Fluocinolone (topical): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluocinolone (topical): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/389350?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluocinolone-topical-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluocinolone (topical): Patient drug information&quot;</a> and <a href=\"topic.htm?path=fluocinolone-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fluocinolone (topical): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097444\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Capex;</li>\n      <li>Derma-Smoothe/FS Body;</li>\n      <li>Derma-Smoothe/FS Scalp;</li>\n      <li>Synalar;</li>\n      <li>Synalar (Cream);</li>\n      <li>Synalar (Ointment);</li>\n      <li>Synalar TS;</li>\n      <li>Xilapak</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097445\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Derma-Smoothe/FS;</li>\n      <li>Synalar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097458\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Corticosteroid, Topical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100671\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note: </b>Dosage should be based on severity of disease and patient response; use smallest amount for shortest period of time. Therapy should be discontinued when control is achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Atopic dermatitis:</b> Topical: Body oil: Apply thin film to affected area 3 times daily </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Corticosteroid-responsive dermatoses:</b> Topical: Cream, ointment, solution: Apply a thin layer to affected area 2 to 4 times daily; may use occlusive dressings to manage psoriasis or recalcitrant conditions </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>Scalp psoriasis:</b> Topical: Scalp oil: Massage thoroughly into wet or dampened hair/scalp; cover with shower cap. Leave on overnight (or for at least 4 hours). Remove by washing hair with shampoo and rinsing thoroughly. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>Seborrheic dermatitis of the scalp:</b> Topical: Shampoo: Apply no more than 1 ounce to scalp once daily; work into lather and allow to remain on scalp for ~5 minutes. Remove from hair and scalp by rinsing thoroughly with water. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100670\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=fluocinolone-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fluocinolone (topical): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note: </b>Dosage should be based on severity of disease and patient response; use smallest amount for shortest period of time. Therapy should be discontinued when control is achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Atopic dermatitis, moderate to severe:</b> Topical: Body oil: Infants &ge;3 months, Children, and Adolescents: Moisten skin; apply a thin film to affected area twice daily; do not use for longer than 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Corticosteroid-responsive dermatoses:</b> Topical: Cream, ointment, solution: Children and Adolescents: Refer to adult dosing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100673\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46330220\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46330221\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100716\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synalar: 0.025% (120 g) [contains cetyl alcohol, edetate disodium, methylparaben, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.01% (15 g, 60 g); 0.025% (15 g, 60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synalar (Cream): 0.025% [contains cetyl alcohol, edetate disodium, methylparaben, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synalar (Ointment): 0.025%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synalar TS: 0.01% [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xilapak: 0.01% [contains butylparaben, cetyl alcohol, methylparaben, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oil, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Derma-Smoothe/FS Body: 0.01% (118.28 mL) [contains isopropyl alcohol, peanut oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Derma-Smoothe/FS Scalp: 0.01% (118.28 mL) [contains isopropyl alcohol, peanut oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.01% (118.28 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synalar: 0.025% (120 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.025% (15 g, 60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Shampoo, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Capex: 0.01% (120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synalar: 0.01% (60 mL, 90 mL) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.01% (60 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097456\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100675\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Topical:  Not for oral, ophthalmic, or intravaginal use; do not apply to the face, axillae, groin, or diaper area unless directed by healthcare provider.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Body oil: Apply the least amount necessary to cover the affected area; do not apply to intertriginous areas. For pediatric patients, moisten skin prior to application.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, ointment, topical solution: Apply sparingly in a thin film; rub in lightly. In hairy sites, the hair should be parted to allow direct contact with the lesion. Occlusive dressings may be helpful in managing psoriasis or recalcitrant conditions, but should not be used if an infection develops.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Shampoo: Shake well before use; do not bandage, wrap, or cover treated scalp area unless directed by healthcare provider.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097446\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Body oil:</b> Treatment of moderate to severe atopic dermatitis in pediatric patients &ge;3 months; treatment of atopic dermatitis in adults</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cream, ointment, topical solution:</b> Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Scalp oil:</b> Treatment of psoriasis of the scalp in adults</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Shampoo:</b> Treatment of seborrheic dermatitis of the scalp</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097421\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Capex may be confused with Kapidex [DSC]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fluocinolone may be confused with fluocinonide</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097485\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Cardiovascular: Intracranial hypertension (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Central nervous system: Telangiectasia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Dermatologic: Acneiform eruptions, allergic contact dermatitis, atopic dermatitis (secondary), burning, dryness, erythema, folliculitis, irritation, itching, hypertrichosis, hypopigmentation, keratosis pilaris, miliaria, papules, perioral dermatitis, pustules, shiny skin, skin atrophy, striae</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Endocrine &amp; metabolic: Cushing's syndrome, HPA axis suppression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Otic: Ear infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Miscellaneous: Herpes simplex, secondary infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097474\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to fluocinolone or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Viral (eg, herpes, varicella) lesions of the skin; bacterial or fungal skin infections; parasitic infections; skin manifestations relating to tuberculosis or syphilis; eruptions following vaccinations; application to the eye</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097475\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact dermatitis: Allergic contact dermatitis can occur, it is usually diagnosed by failure to heal rather than clinical exacerbation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Local effects: Local adverse reactions may occur (eg, skin atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection miliaria); may be irreversible. Local adverse reactions are more likely to occur with occlusive and/or prolonged use. If irritation develops, discontinued use and institute appropriate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin infections: Concomitant skin infections may be present or develop during therapy; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peanut oil: Derma-Smoothe/FS products may contain peanut oil; use caution in peanut-sensitive individuals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not for oral, ophthalmic, or intravaginal use; do not apply to the face, axillae, groin, or diaper area unless directed by health care provider. Use the least amount needed to cover the affected area; discontinue when control is achieved. If improvement is not seen within 2 weeks, reassess.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Shampoo: Has not been proven to be effective in corticosteroid responsive dermatoses other than seborrheic dermatitis of the scalp.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299349\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097493\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9130&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097469\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097470\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed with corticosteroids in animal reproduction studies. In general, the use of topical corticosteroids during pregnancy is not considered to have significant risk; however, intrauterine growth retardation in the infant has been reported (rare). The use of large amounts or for prolonged periods of time should be avoided (Reed 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097473\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Systemic corticosteroids are excreted in human milk. It is not known if sufficient quantities of fluocinolone are absorbed following topical administration to produce detectable amounts in breast milk. Hypertension in the breast-feeding infant has been reported following corticosteroid ointment applied to the nipples (Reed 1997). The manufacturer recommends that caution be exercised when administering fluocinolone to breast-feeding women. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100678\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Growth in pediatric patients; HPA axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test); signs of bacterial or fungal infection </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100660\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A<sub>2</sub> inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid.  Fluocinolone has low to intermediate range potency (dosage-form dependent).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100662\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Dependent on formulation, amount applied, nature of skin at application site; may be increased with inflammation or occlusion </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine; bile </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100718\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Fluocinolone Acetonide External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (15 g): $44.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025% (15 g): $35.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Synalar External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025% (120 g): $542.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Synalar (Cream) External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025% (375 g): $542.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Synalar (Ointment) External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025% (375 g): $542.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Synalar TS External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (1): $579.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Xilapak External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (1): $7,341.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oil</b> (Derma-Smoothe/FS Body External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (118.28 mL): $308.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oil</b> (Derma-Smoothe/FS Scalp External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (118.28 mL): $312.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oil</b> (Fluocinolone Acetonide Body External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (118.28 mL): $220.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oil</b> (Fluocinolone Acetonide Scalp External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (118.28 mL): $222.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Fluocinolone Acetonide External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025% (15 g): $33.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Synalar External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025% (120 g): $542.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Shampoo</b> (Capex External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (120 mL): $458.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Fluocinolone Acetonide External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (60 mL): $187.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Synalar External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (60 mL): $579.73</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961973\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adermina (CL);</li>\n      <li>Aplosyn (PH);</li>\n      <li>Bratofil (VE);</li>\n      <li>Bravoderm (ID);</li>\n      <li>Cinolon (ID);</li>\n      <li>Cortoderm (ZA);</li>\n      <li>Dermalar (IL);</li>\n      <li>Dermasolon Gel (ID);</li>\n      <li>Dermolar (AE, BH, KW, QA, SA);</li>\n      <li>Emderm (IN);</li>\n      <li>Esacinone (AE, BH, CY, EG, IQ, IR, JO, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Fluciderm (ET, ID, MY);</li>\n      <li>Flucinar (BG, CZ, DE, HN, LV, PL, VN);</li>\n      <li>Flucort (ET, IN, TW, VN);</li>\n      <li>Flucortone (TW);</li>\n      <li>Flulone (AR);</li>\n      <li>Flunolone (TW);</li>\n      <li>Flunolone-V (SG, TH);</li>\n      <li>Fluo-A (TW);</li>\n      <li>Fluociclerc (PY);</li>\n      <li>Fluocid Forte (ES);</li>\n      <li>Fluocinolona (PY);</li>\n      <li>Fluoderm (ZA);</li>\n      <li>Fluonid (MY);</li>\n      <li>Flutsynar (UA);</li>\n      <li>Fungakil (BD);</li>\n      <li>Gelargin (CZ);</li>\n      <li>Inoderm (ID);</li>\n      <li>Jellin (DE);</li>\n      <li>Localyn (IT);</li>\n      <li>Luci (IN);</li>\n      <li>Paracort (TW);</li>\n      <li>Petralar (JO, KW);</li>\n      <li>Radiocin (AE, BF, BH, BJ, CI, CY, EG, GH, GM, GN, IQ, IR, JO, KE, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, UG, YE, ZM);</li>\n      <li>Skinalar (BD, LK);</li>\n      <li>Supricort (PE);</li>\n      <li>Synalar (AE, AT, BB, BE, BF, BH, BJ, CH, CI, CY, DK, EE, EG, ES, ET, FR, GB, GH, GM, GN, GR, HK, IQ, IR, IS, JO, KE, LB, LR, LY, MA, ML, MR, MT, MU, MW, NE, NG, NO, NZ, OM, PK, PT, QA, SA, SC, SD, SE, SI, SK, SL, SN, SY, TN, TR, TZ, UG, YE, ZM, ZW);</li>\n      <li>Synalar Simple (UY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Capex shampoo (fluocinolone acetonide) [prescribing information]. Fort Worth, TX: Galderma Laboratories; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Derma-Smoothe/FS body oil (fluocinolone acetonide) [prescribing information]. Manasquan, NJ: Royal Pharmaceuticals; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Derma-Smoothe/FS scalp oil (fluocinolone acetonide) [prescribing information]. Manasquan, NJ: Royal Pharmaceuticals; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Derma-Smoothe/FS topical oil (fluocinolone acetonide) [product monograph]. Mississauga, Ontario, Canada: Hill Dermaceuticals; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi's sarcoma. <i>J Natl Cancer Inst.</i> 2002;94(22):1712-1718.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluocinolone-topical-drug-information/abstract-text/12441327/pubmed\" target=\"_blank\" id=\"12441327\">12441327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reed, BR. Dermatologic drugs, pregnancy, and lactation. A conservative guide. <i>Arch Dermatol</i>. 1997;133(7):894-898.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluocinolone-topical-drug-information/abstract-text/9236528/pubmed\" target=\"_blank\" id=\"9236528\">9236528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synalar cream (fluocinolone acetonide) [prescribing information]. Fairfield, NJ: Medimetriks Pharmaceuticals; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synalar ointment (fluocinolone acetonide) [prescribing information]. Fairfield, NJ: Medimetriks Pharmaceuticals; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synalar ointment and solution (fluocinolone acetonide) [product monograph]. Laval, Quebec, Canada: Valeant Canada; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synalar topical solution (fluocinolone acetonide) [prescribing information]. Fairfield, NJ: Medimetriks Pharmaceuticals; May 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9130 Version 163.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8097444\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8097445\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8097458\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8100671\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F8100670\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8100673\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F46330220\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F46330221\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8100716\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8097456\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8100675\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8097446\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8097421\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8097485\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8097474\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8097475\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299349\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8097493\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8097469\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8097470\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F8097473\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F8100678\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8100660\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8100662\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8100718\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961973\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9130|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluocinolone-topical-patient-drug-information\" class=\"drug drug_patient\">Fluocinolone (topical): Patient drug information</a></li><li><a href=\"topic.htm?path=fluocinolone-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">Fluocinolone (topical): Pediatric drug information</a></li></ul></div></div>","javascript":null}